Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer | Zendy

Manuel Caitano Maia | Zendy; Allan Andresson Lima Pereira | Zendy; Liana Valente Lage | Zendy; N. Fraile | Zendy; Victor Van Vaisberg | Zendy; Guilherme Konishi Kudo | Zendy; Romualdo BarrosoSousa | Zendy; Diogo Assed Bastos | Zendy; Carlos Dzik | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer

Author(s) -

Manuel Caitano Maia,

Allan Andresson Lima Pereira,

Liana Valente Lage,

N. Fraile,

Victor Van Vaisberg,

Guilherme Konishi Kudo,

Romualdo BarrosoSousa,

Diogo Assed Bastos,

Carlos Dzik

Publication year - 2017

Publication title -

journal of global oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.002

H-Index - 17

ISSN - 2378-9506

DOI - 10.1200/jgo.2016.007807

Subject(s) - medicine , docetaxel , prostate cancer , oncology , castration , cancer , hormone

Limited data are available about the tolerability and clinical outcomes of elderly patients with metastatic castration-resistant prostate cancer (mCRPC) who are treated with docetaxel. We evaluated the efficacy and safety of docetaxel as first-line chemotherapy for patients with mCRPC who were treated in our institution.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research